These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 3204077)

  • 1. Tobramycin dosing in mechanically ventilated patients. Inaccuracy of a 'rule of thumb'.
    Martin C; Mallet MN; Saux P; Bruguerolle B; Herat V; Gouin F
    J Antimicrob Chemother; 1988 Oct; 22(4):505-11. PubMed ID: 3204077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Serum level-adjusted dosage of once-daily aminoglycoside therapy in critical illness: results of a prospective study].
    Reimann IR; Meier-Hellmann A; Pfeifer R; Traut T; Schilling A; Stein G; Reinhart K; Hoffmann A
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1999 May; 34(5):288-95. PubMed ID: 10372218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring of a single post-infusion blood sample to estimate the actual peak and trough concentration of tobramycin in critically ill patients.
    Reimann IR; Meier-Hellmann A; Traut T; Reinhart K; Hoffmann A
    Exp Toxicol Pathol; 2003 Jun; 54(5-6):493-8. PubMed ID: 12877363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung Pharmacokinetics of Tobramycin by Intravenous and Nebulized Dosing in a Mechanically Ventilated Healthy Ovine Model.
    Dhanani JA; Diab S; Chaudhary J; Cohen J; Parker SL; Wallis SC; Boidin C; Barnett A; Chew M; Roberts JA; Fraser JF
    Anesthesiology; 2019 Aug; 131(2):344-355. PubMed ID: 31107274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study evaluating tobramycin pharmacokinetics and optimal once daily dosing in burn patients.
    Lee C; Walker SAN; Walker SE; Seto W; Simor A; Jeschke M
    Burns; 2017 Dec; 43(8):1766-1774. PubMed ID: 28647460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Administration of tobramycin aerosols in patients with nosocomial pneumonia: a preliminary study].
    Le Conte P; Potel G; Clémenti E; Legras A; Villers D; Bironneau E; Cousson J; Baron D
    Presse Med; 2000 Jan; 29(2):76-8. PubMed ID: 10682031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin.
    Hermida J; Tutor JC
    Ther Drug Monit; 2006 Jun; 28(3):326-31. PubMed ID: 16778715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tobramycin population pharmacokinetics in neonates.
    de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
    Clin Pharmacol Ther; 1997 Oct; 62(4):392-9. PubMed ID: 9357390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis.
    Massie J; Cranswick N
    J Paediatr Child Health; 2006 Oct; 42(10):601-5. PubMed ID: 16972966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung distribution and pharmacokinetics of aerosolized tobramycin.
    Le Conte P; Potel G; Peltier P; Horeau D; Caillon J; Juvin ME; Kerguéris MF; Bugnon D; Baron D
    Am Rev Respir Dis; 1993 May; 147(5):1279-82. PubMed ID: 8484643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
    Buijk SE; Mouton JW; Gyssens IC; Verbrugh HA; Bruining HA
    Intensive Care Med; 2002 Jul; 28(7):936-42. PubMed ID: 12122533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic variability of extended interval tobramycin in burn patients.
    Bracco D; Landry C; Dubois MJ; Eggimann P
    Burns; 2008 Sep; 34(6):791-6. PubMed ID: 18395988
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive performance of Sawchuk-Zaske and Bayesian dosing methods for tobramycin.
    Rodvold KA; Blum RA
    J Clin Pharmacol; 1987; 27(5):419-24. PubMed ID: 3693587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients.
    Badia JR; Soy D; Adrover M; Ferrer M; Sarasa M; Alarcón A; Codina C; Torres A
    J Antimicrob Chemother; 2004 Aug; 54(2):508-14. PubMed ID: 15215224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hospital acquired gram-negative pneumonias: response rate and dosage requirements with individualized tobramycin therapy.
    Cipolle RJ; Seifert RD; Zaske DE; Strate RG
    Ther Drug Monit; 1980; 2(4):359-63. PubMed ID: 7222190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of aminoglycoside dosing and estimated glomerular filtration rate in determining gentamicin and tobramycin area under the curve and clearance.
    Lim AK; Mathanasenarajah G; Larmour I
    Intern Med J; 2015 Mar; 45(3):319-29. PubMed ID: 25581282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New schedule for tobramycin administration.
    Lawson RD; Bodey GP; Pan T; Smith TL
    Antimicrob Agents Chemother; 1980 May; 17(5):834-7. PubMed ID: 7396470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.